[Anticoagulation for stroke prevention. An update].
Given the projected rising prevalence of atrial fibrillation in the near future, an increasing number of older patients will have to be treated in order to prevent stroke and systemic embolism. This article summarizes recent developments in antithrombotic treatment and risk stratification for patients with atrial fibrillation and intends to abate the still prevailing reluctance towards anticoagulation in elderly patients.
Koennecke
H C
HC
Gefässzentrum Berlin, Abteilung für Neurologie, Ev. Krankenhaus Königin Elisabeth Herzberge, Berlin. h.koennecke@keh-berlin.de
D000208:Acute Disease; D000284:Administration, Oral; D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D000925:Anticoagulants / Q000009:adverse effects / Q000627:therapeutic use*; D001281:Atrial Fibrillation / Q000150:complications; D002544:Cerebral Infarction / Q000209:etiology / Q000517:prevention & control*; D004359:Drug Therapy, Combination; D005343:Fibrinolytic Agents / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D012307:Risk Factors; D055502:Secondary Prevention; D014812:Vitamin K / Q000037:antagonists & inhibitors
D000925:Anticoagulants; D005343:Fibrinolytic Agents; D014812:Vitamin K